

Russell D Cohen

List of Publications by Citations

Source: <https://exaly.com/author-pdf/5322224/russell-d-cohen-publications-by-citations.pdf>

Version: 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

100
papers

4,986
citations

32
h-index

70
g-index

105
ext. papers

5,775
ext. citations

3.4
avg, IF

5.46
L-index

#	Paper	IF	Citations
100	Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry. <i>Clinical Gastroenterology and Hepatology</i> , 2006 , 4, 621-30	6.9	724
99	Serious infection and mortality in patients with Crohn's disease: more than 5 years of follow-up in the TREAT registry. <i>American Journal of Gastroenterology</i> , 2012 , 107, 1409-22	0.7	513
98	Prevalence of nonadherence with maintenance mesalamine in quiescent ulcerative colitis. <i>American Journal of Gastroenterology</i> , 2001 , 96, 2929-33	0.7	342
97	Intravenous cyclosporin in ulcerative colitis: a five-year experience. <i>American Journal of Gastroenterology</i> , 1999 , 94, 1587-92	0.7	250
96	An open-label study of the human anti-TNF monoclonal antibody adalimumab in subjects with prior loss of response or intolerance to infliximab for Crohn's disease. <i>American Journal of Gastroenterology</i> , 2004 , 99, 1984-9	0.7	221
95	Are dysplasia and colorectal cancer endoscopically visible in patients with ulcerative colitis?. <i>Gastrointestinal Endoscopy</i> , 2007 , 65, 998-1004	5.2	204
94	A meta-analysis and overview of the literature on treatment options for left-sided ulcerative colitis and ulcerative proctitis. <i>American Journal of Gastroenterology</i> , 2000 , 95, 1263-76	0.7	195
93	Infliximab in Crohn's disease: first anniversary clinical experience. <i>American Journal of Gastroenterology</i> , 2000 , 95, 3469-77	0.7	173
92	Absence of infliximab in infants and breast milk from nursing mothers receiving therapy for Crohn's disease before and after delivery. <i>Journal of Clinical Gastroenterology</i> , 2009 , 43, 613-6	3	123
91	The cost of hospitalization in Crohn's disease. <i>American Journal of Gastroenterology</i> , 2000 , 95, 524-30	0.7	120
90	Autoimmune disease concomitance among inflammatory bowel disease patients in the United States, 2001-2002. <i>Inflammatory Bowel Diseases</i> , 2008 , 14, 738-43	4.5	98
89	Infliximab decreases resource use among patients with Crohn's disease. <i>Journal of Clinical Gastroenterology</i> , 2002 , 35, 151-6	3	96
88	Open-label study of adalimumab in patients with ulcerative colitis including those with prior loss of response or intolerance to infliximab. <i>Inflammatory Bowel Diseases</i> , 2009 , 15, 1302-7	4.5	90
87	Medical management of left-sided ulcerative colitis and ulcerative proctitis: critical evaluation of therapeutic trials. <i>Inflammatory Bowel Diseases</i> , 2006 , 12, 979-94	4.5	77
86	Side-to-side isoperistaltic strictureplasty in extensive Crohn's disease: a prospective longitudinal study. <i>Annals of Surgery</i> , 2000 , 232, 401-8	7.8	77
85	Co-occurrence and comorbidities in patients with immune-mediated inflammatory disorders: an exploration using US healthcare claims data, 2001-2002. <i>Current Medical Research and Opinion</i> , 2006 , 22, 989-1000	2.5	76
84	Complete response of metastatic melanoma in a patient with Crohn's disease simultaneously receiving anti- CTLA-4 and anti-PD1 antibodies 2019 , 7, 1		75

83	Quality of life after proctocolectomy with ileoanal anastomosis for patients with ulcerative colitis. <i>Journal of Clinical Gastroenterology</i> , 2006 , 40, 669-77	3	67
82	Mesalamine delivery systems: do they really make much difference?. <i>Advanced Drug Delivery Reviews</i> , 2005 , 57, 281-302	18.5	65
81	Use of Biologic Therapy by Pregnant Women With Inflammatory Bowel Disease Does Not Affect Infant Response to Vaccines. <i>Clinical Gastroenterology and Hepatology</i> , 2018 , 16, 99-105	6.9	63
80	A comparison of the quality of life in patients with severe ulcerative colitis after total colectomy versus medical treatment with intravenous cyclosporin. <i>Inflammatory Bowel Diseases</i> , 1999 , 5, 1-10	4.5	58
79	Serum 25-hydroxyvitamin D concentration is inversely associated with mucosal inflammation in patients with ulcerative colitis. <i>American Journal of Clinical Nutrition</i> , 2016 , 104, 113-20	7	57
78	Managing immunogenic responses to infliximab: treatment implications for patients with Crohn's disease. <i>Drugs</i> , 2004 , 64, 1767-77	12.1	57
77	Infliximab for Crohn's Disease: More Than 13 Years of Real-world Experience. <i>Inflammatory Bowel Diseases</i> , 2018 , 24, 490-501	4.5	53
76	Safety and Efficacy of Combination Treatment With Calcineurin Inhibitors and Vedolizumab in Patients With Refractory Inflammatory Bowel Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2019 , 17, 486-493	6.9	53
75	Clinical guidelines for the medical management of left-sided ulcerative colitis and ulcerative proctitis: summary statement. <i>Inflammatory Bowel Diseases</i> , 2006 , 12, 972-8	4.5	53
74	Advances in the management of Crohn's disease: economic and clinical potential of infliximab. <i>Clinical Therapeutics</i> , 1998 , 20, 1009-28	3.5	46
73	Fecal Calprotectin in Assessing Endoscopic and Histological Remission in Patients with Ulcerative Colitis. <i>Digestive Diseases and Sciences</i> , 2018 , 63, 1294-1301	4	44
72	Budesonide Multimatrix Is Efficacious for Mesalamine-refractory, Mild to Moderate Ulcerative Colitis: A Randomised, Placebo-controlled Trial. <i>Journal of Crohns and Colitis</i> , 2017 , 11, 785-791	1.5	40
71	Efficacy and safety of repeated infliximab infusions for Crohn's disease: 1-year clinical experience. <i>Inflammatory Bowel Diseases</i> , 2001 , 7 Suppl 1, S17-22	4.5	40
70	Pregnancy and Neonatal Outcomes After Fetal Exposure to Biologics and Thiopurines Among Women With Inflammatory Bowel Disease. <i>Gastroenterology</i> , 2021 , 160, 1131-1139	13.3	36
69	Effects of fistula on healthcare costs and utilization for patients with Crohn's disease treated in a managed care environment. <i>Inflammatory Bowel Diseases</i> , 2008 , 14, 1707-14	4.5	34
68	Direct and indirect healthcare resource utilization and costs associated with ulcerative colitis in a privately-insured employed population in the US. <i>Journal of Medical Economics</i> , 2015 , 18, 447-56	2.4	32
67	Natalizumab in Crohn's disease: results from a US tertiary inflammatory bowel disease center. <i>Inflammatory Bowel Diseases</i> , 2013 , 19, 621-6	4.5	30
66	The Effect of Maternal Peripartum Anti-TNF Use on Infant Immune Response. <i>Digestive Diseases and Sciences</i> , 2016 , 61, 1622-7	4	29

65	Factors associated with readmission to the hospital within 30 days in patients with inflammatory bowel disease. <i>PLoS ONE</i> , 2017 , 12, e0182900	3.7	28
64	The Use of Vedolizumab in Preventing Postoperative Recurrence of Crohn's Disease. <i>Inflammatory Bowel Diseases</i> , 2018 , 24, 502-509	4.5	28
63	Ustekinumab Is Effective for the Treatment of Chronic Antibiotic-Refractory Pouchitis. <i>Digestive Diseases and Sciences</i> , 2019 , 64, 3596-3601	4	25
62	Predictors of adalimumab dose escalation in patients with Crohn's disease at a tertiary referral center. <i>Inflammatory Bowel Diseases</i> , 2012 , 18, 10-6	4.5	25
61	Systematic Review: Rectal Therapies for the Treatment of Distal Forms of Ulcerative Colitis. <i>Inflammatory Bowel Diseases</i> , 2015 , 21, 1719-36	4.5	25
60	Vedolizumab as Induction and Maintenance for Inflammatory Bowel Disease: 12-month Effectiveness and Safety. <i>Inflammatory Bowel Diseases</i> , 2018 , 24, 849-860	4.5	24
59	The Safety Profile of Vedolizumab in Ulcerative Colitis and Crohn's Disease: 4 Years of Global Post-marketing Data. <i>Journal of Crohns and Colitis</i> , 2020 , 14, 192-204	1.5	23
58	Mucosal healing is associated with improved long-term outcome of maintenance therapy with natalizumab in Crohn's disease. <i>Inflammatory Bowel Diseases</i> , 2013 , 19, 2577-83	4.5	22
57	Optimizing conventional therapy for inflammatory bowel disease. <i>Current Gastroenterology Reports</i> , 2008 , 10, 585-90	5	22
56	Nicotine in Ulcerative Colitis. <i>BioDrugs</i> , 1996 , 5, 169-174		21
55	Effectiveness of Ustekinumab Dose Escalation in Patients With Crohn's Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2021 , 19, 104-110	6.9	21
54	Crohn's disease and Takayasu's arteritis. <i>Journal of Clinical Gastroenterology</i> , 2002 , 34, 454-6	3	19
53	Surveillance of IBD Using High Definition Colonoscopes Does Not Miss Adenocarcinoma in Patients with Low-grade Dysplasia. <i>Inflammatory Bowel Diseases</i> , 2016 , 22, 631-7	4.5	19
52	Low-Dose Metronidazole is Associated With a Decreased Rate of Endoscopic Recurrence of Crohn's Disease After Ileal Resection: A Retrospective Cohort Study. <i>Journal of Crohns and Colitis</i> , 2019 , 13, 1158-1162 ¹⁸	1.5	18
51	Ciclosporin Therapy After Infliximab Failure in Hospitalized Patients With Acute Severe Colitis is Effective and Safe. <i>Journal of Crohns and Colitis</i> , 2019 , 13, 1105-1110	1.5	17
50	The incidence and predictors of lupus-like reaction in patients with IBD treated with anti-TNF therapies. <i>Inflammatory Bowel Diseases</i> , 2013 , 19, 2778-86	4.5	17
49	Age of Diagnosis is Associated with Disease Presentation and Therapeutic Complications in Patients with Crohn's Disease. <i>Inflammatory Bowel Diseases</i> , 2016 , 22, 1027-31	4.5	17
48	Higher Thioguanine Nucleotide Metabolite Levels are Associated With Better Long-term Outcomes in Patients With Inflammatory Bowel Diseases. <i>Journal of Clinical Gastroenterology</i> , 2018 , 52, 537-544	3	17

47	Assessment of peri-polyp biopsy specimens of flat mucosa in patients with inflammatory bowel disease. <i>Gastrointestinal Endoscopy</i> , 2018 , 87, 1304-1309	5.2	16
46	Medical therapy for ulcerative colitis: the state of the art and beyond. <i>Current Gastroenterology Reports</i> , 2004 , 6, 488-95	5	16
45	Prevalence of Antibodies Against JC Virus in Patients With Refractory Crohn's Disease and Effects of Natalizumab Therapy. <i>Clinical Gastroenterology and Hepatology</i> , 2015 , 13, 1919-25	6.9	15
44	Collagenous gastritis: an unusual association with profound weight loss. <i>Archives of Pathology and Laboratory Medicine</i> , 2004 , 128, 229-32	5	15
43	Efficacy and safety of induction therapy with calcineurin inhibitors followed by vedolizumab maintenance in 71 patients with severe steroid-refractory ulcerative colitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2020 , 51, 637-643	6.1	15
42	Correlation of nuclear morphometry and DNA ploidy in rectal cancer. <i>Diseases of the Colon and Rectum</i> , 1991 , 34, 449-54	3.1	13
41	Differential risk of disease progression between isolated anastomotic ulcers and mild ileal recurrence after ileocolonic resection in patients with Crohn's disease. <i>Gastrointestinal Endoscopy</i> , 2019 , 90, 269-275	5.2	12
40	Approach to Optimize Anti-TNF- α Therapy in Patients With IBD. <i>Current Treatment Options in Gastroenterology</i> , 2016 , 14, 83-90	2.5	12
39	Pharmacoeconomics and quality of life of current and emerging biologic therapies for inflammatory bowel disease. <i>Current Treatment Options in Gastroenterology</i> , 2007 , 10, 185-94	2.5	12
38	Evolving medical therapies for ulcerative colitis. <i>Current Gastroenterology Reports</i> , 2002 , 4, 497-505	5	12
37	Efficacy and Follow-up of Segmental or Subtotal Colectomy in Patients With Colitis-Associated Neoplasia. <i>Clinical Gastroenterology and Hepatology</i> , 2019 , 17, 205-206	6.9	11
36	Assessment of variables associated with smoking cessation in Crohn's disease. <i>Digestive Diseases and Sciences</i> , 2012 , 57, 1026-32	4	11
35	First two patients with ulcerative colitis who developed classical thrombotic thrombocytopenic purpura successfully treated with medical therapy and plasma exchange. <i>Journal of Clinical Apheresis</i> , 2002 , 17, 204-6	3.2	11
34	Immunomodulatory agents and other medical therapies in inflammatory bowel disease. <i>Current Opinion in Gastroenterology</i> , 1995 , 11, 321-330	3	10
33	Incidence and predictors of clinical response, re-induction dose, and maintenance dose escalation with certolizumab pegol in Crohn's disease. <i>Inflammatory Bowel Diseases</i> , 2014 , 20, 1722-8	4.5	9
32	A comparison of the risk of postoperative recurrence between African-American and Caucasian patients with Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2018 , 48, 933-940	6.1	8
31	What to Do When Biologic Agents Are Not Working in Inflammatory Bowel Disease Patients. <i>Gastroenterology and Hepatology</i> , 2015 , 11, 657-65	0.7	8
30	Risk Factors for Clostridium difficile Isolation in Inflammatory Bowel Disease: A Prospective Study. <i>Digestive Diseases and Sciences</i> , 2018 , 63, 1016-1024	4	7

29	Once-daily MMX mesalamine for the treatment of mild-to-moderate ulcerative colitis. <i>Therapeutics and Clinical Risk Management</i> , 2007 , 3, 919-27	2.9	7
28	Abnormal Pouchogram Predicts Pouch Failure Even in Asymptomatic Patients. <i>Diseases of the Colon and Rectum</i> , 2019 , 62, 463-469	3.1	7
27	Daily Aspirin Use Does Not Impact Clinical Outcomes in Patients With Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2021 , 27, 236-241	4.5	7
26	Maintaining remission in ulcerative colitis--role of once daily extended-release mesalamine. <i>Drug Design, Development and Therapy</i> , 2011 , 5, 111-6	4.4	5
25	How should we treat severe acute steroid-refractory ulcerative colitis?. <i>Inflammatory Bowel Diseases</i> , 2009 , 15, 150-1	4.5	5
24	Pharmacoeconomic considerations for inflammatory bowel disease in the era of biological therapies. <i>Expert Review of Gastroenterology and Hepatology</i> , 2007 , 1, 101-12	4.2	5
23	Postoperative management of ulcerative colitis and Crohn's disease. <i>Current Gastroenterology Reports</i> , 2005 , 7, 492-9	5	5
22	Outcome of elective switching to vedolizumab in inflammatory bowel disease patients under tumor necrosis factor antagonist-maintained clinical remission. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2019 , 34, 2090-2095	4	4
21	IBD: the drugs work...but do the patients?. <i>American Journal of Gastroenterology</i> , 2003 , 98, 722-3	0.7	4
20	Infliximab decreases resource utilization in patients with Crohn's disease. <i>American Journal of Gastroenterology</i> , 2000 , 95, 2499-2500	0.7	4
19	The Correlation between Vitamin D Levels and the Risk of Postoperative Recurrence in Crohn's Disease. <i>Digestion</i> , 2021 , 102, 767-775	3.6	4
18	Risk factors and treatment outcomes of peristomal pyoderma gangrenosum in patients with inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2020 , 51, 1365-1372	6.1	3
17	Inpatient Therapy With Calcineurin Inhibitors in Severe Ulcerative Colitis. <i>Inflammatory Bowel Diseases</i> , 2021 , 27, 1620-1625	4.5	3
16	Clinical Response and Complications are not Associated with Drug Levels in Patients with Severe Ulcerative Colitis on IV Cyclosporine Induction Therapy. <i>Inflammatory Bowel Diseases</i> , 2018 , 24, 1291-1297	4.5	2
15	Management of refractory ulcerative colitis. <i>Current Treatment Options in Gastroenterology</i> , 2006 , 9, 234-45	2.5	2
14	P-074 Age of Diagnosis Is Associated with the Severity of Adverse Effects to Therapy in Crohn's Disease Patients. <i>Inflammatory Bowel Diseases</i> , 2013 , 19, S55	4.5	1
13	Response:. <i>Gastrointestinal Endoscopy</i> , 2008 , 67, 1009-1010	5.2	1
12	Infliximab as first-line therapy for severe Crohn's disease?. <i>Inflammatory Bowel Diseases</i> , 2002 , 8, 58-9; discussion 63-5	4.5	1

11	Evolving medical therapies for ulcerative colitis. <i>Current Gastroenterology Reports</i> , 2001 , 3, 464-70	5	1
10	Vedolizumab for perianal fistulizing Crohn's disease: systematic review and meta-analysis.. <i>Intestinal Research</i> , 2022 ,	4.1	1
9	Fecal Calprotectin Is Highly Effective to Detect Endoscopic Ulcerations in Crohn's Disease Regardless of Disease Location. <i>Inflammatory Bowel Diseases</i> , 2021 , 27, 1008-1016	4.5	1
8	Letter: is unrealised adult height resulting from paediatric Crohn's disease associated with a potential reduction in lifetime earnings?. <i>Alimentary Pharmacology and Therapeutics</i> , 2020 , 52, 559-560	6.1	1
7	Predictability of simple endoscopic score for Crohn's disease for postoperative outcomes in Crohn's disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021 , 36, 2785-2793	4	0
6	Direct and Indirect Utilization and Costs Associated With Ulcerative Colitis. <i>Inflammatory Bowel Diseases</i> , 2012 , 18, S41	4.5	
5	Transcending therapeutic conventions: New realities in the treatment of Crohn's disease. <i>Inflammatory Bowel Diseases</i> , 2001 , 7, S1-S1	4.5	
4	UC CANCERS IN PSC: RIGHT SIDED OR WRONG?. <i>Inflammatory Bowel Diseases</i> , 1998 , 4, 330	4.5	
3	Nonmedical Switching of Biosimilars in Patients With Inflammatory Bowel Disease. <i>Gastroenterology and Hepatology</i> , 2017 , 13, 697-699	0.7	
2	A Comprehensive Review of Topical Therapies for Distal Ulcerative Colitis. <i>Gastroenterology and Hepatology</i> , 2020 , 16, 21-27	0.7	
1	Rare and Well Done: Endoscopic Control of Colonic Hemorrhage in Severe Ulcerative Colitis.. <i>Digestive Diseases and Sciences</i> , 2022 , 67, 805	4	